ORDER

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs-055/2017 dated 18/12/2017 through e-procurement system i.e., CPP portal on 18/12/2017 for supply of drugs for the year 2018-2020.

Whereas, M/S Cachet Pharmaceuticals Pvt. Ltd (hereafter called as the firm) addressed at 415, SHAH NAHAR, Dr. E. Moses Road, Worli, Mumbai-400018 had participated in tender. The firm was awarded 07 drugs by Bureau of Pharma Public Sector Undertakings of India, New Delhi vide letter dated 08/10-05-2018 of acceptance for price agreement for supply of 7 drugs for 2 years period as per tender provision. The firm was asked to submit performance security for Rs. 5634875/- within 15 days as per clause 10 of tender document.

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had also issued purchase order’s of 5 drugs out of 7 accepted drugs vide letter dated 08/10-05-2018 of acceptance for price agreement as per tender provision. The details of purchase orders for 5 drugs are as under:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Purchase order no. &amp; date</th>
<th>Drug code</th>
<th>Description of Drug</th>
<th>Quantity</th>
<th>Delivery date</th>
<th>Value of purchase order (including GST) in Rs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BPPI/1765 dated 26.02.18</td>
<td>512</td>
<td>Aceclofenac 100 mg + Paracetamol 325 mg + Serratopetidase 15 mg Tablets</td>
<td>160000</td>
<td>12.04.18</td>
<td>1,157,632.00</td>
</tr>
<tr>
<td>2</td>
<td>BPPI/1789 dated 26.02.18</td>
<td>1072</td>
<td>Tamsulosin Modified-Release Capsules 0.4 mg</td>
<td>180000</td>
<td>12.04.18</td>
<td>1,312,416.00</td>
</tr>
<tr>
<td>3</td>
<td>BPPI/1792 dated 27.02.18</td>
<td>220</td>
<td>Calcium Carbonate 1250mg (Calcium 500mg + Vitamin D3 250iu film coated Tablet)</td>
<td>600000</td>
<td>13.04.18</td>
<td>1,236,480.00</td>
</tr>
<tr>
<td>4</td>
<td>18000298 dated 22.02.18</td>
<td>50</td>
<td>Azithromycin 500 mg film coated Tablet</td>
<td>200000</td>
<td>06.07.18</td>
<td>8,022,000.00</td>
</tr>
<tr>
<td>5</td>
<td>18000298 dated 22.02.18</td>
<td>239</td>
<td>Cotrimoxazole 5 mg/5 ml syrup</td>
<td>740000</td>
<td>06.07.18</td>
<td>1,265,840.00</td>
</tr>
</tbody>
</table>

Whereas, the firm had neither submitted performance security amount Rs. 5634875/- nor supplied 5 drugs as per details above.

Contd....
Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice on 30/08/2018 to the firm informing about the clause no. 10.4, 11(e), 19.7 & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken:

(i) Forfeit of EMD of Rs.100000/- submitted by you in form of DD No. 021313 from Bank of Baroda
(ii) Consider your bad performance for future dealings & disqualify your company from participating in the tender for the 2 years.
(iii) Recover 5% value of supply order from your pending bills.
(iv) Initiate blacklisting of your company.

Whereas, the firm vide their e-mail dated 14/09/2018 informed that they are unable to pay performance security amount Rs. 5634875/-. Further, the firm have also informed that they are not in the position to supply the drugs.

In view of above, the firm is debarred for a period of 2 years to participate in the tender of Bureau of Pharma Public Sector Undertakings of India, New Delhi for supply of all drugs from date of issuance of this order.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau of Pharma Public Sector Undertakings of India, New Delhi in the matter.

[Signature]
Sachidanand (IIRS)
Chief Executive Officer
Bureau of Pharma PSUs of India, New Delhi

To

Speed post/e-mail

M/S Cachet Pharmaceuticals Pvt. Ltd.(hereafter called as the firm) addressed at 415, SHAH NAHAR, DR. E. Moses Road, Worli, Mumbai-400018